Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We also have generated excellent immunological response against pathogen of concerns, especially Monkeypox, flu, Lassa virus and Marburg virus |
| We also announced our collaboration with Wistar in January of this year and The Wistar Institute’s Vaccine & Immunotherapy Center is uniquely positioned to advance new vaccine formulations to facilitate further expansion and development of vaccine |
| These characteristics suggest superior commercial handling and distribution properties compared with mRNA vaccines, as well as greater manufacturing flexibility |
| A simple analysis of patients who received IMNN-001 and post-chemo maintenance therapy with PARP inhibitors versus PARP inhibitors alone in the control group shows positive impacts |
| We also saw continued benefits in secondary endpoints including a 20% higher R0 tumor resection score and a doubling of CRS 3 chemotherapy response score to approximately 30% in the treatment arm, versus 14% in the control arm |
| So we believe that our technology holds excellent promise in immuno-oncology as our work in providing options to women with ovarian cancer looks very interesting |
| In addition, preclinical studies show that PlaCCine elicits better antibody response kinetic following a single dose, and demonstrate better shelf life of at least 12 months at four degrees Celsius and at least two weeks at very high temperatures of 37 degrees Celsius |
| We've also been using the phrase vaccine of the future to describe our work and that's exactly what our vision is, to be the provider of safe and effective vaccines that are superior to current vaccines in terms of durability and breadth of protection, are stable at workable temperatures, can be manufactured rapidly to respond to evolving pathogen and offer better compliance for mass immunization with no need for device or virus |
| Its stability at regular refrigerator temperatures of 12 months, room temperature stability over at least one month, and stability at high temperatures for at least two weeks plus the immune response duration and the plug-and-play model, using the Plasmid DNA backbone, has shown excellent pre-clinical results that are so important to a commercial vaccine product |
| Importantly, recall that we manufacture our vaccines at our own cGMP facility in Alabama and our decision to manufacture in-house offers us many strategic benefits, but notably, the controls on cost, quality and timelines |
| Our small Phase II is showing promising trends in the ITT population and a strong benefit to standard maintenance PARP inhibitors therapy, which could inform registration study |
| So as you might think, we are very pleased with the duration of response |
| We have made good headway in that direction, so MSK is very likely coming up soon |
| Since OVATION 2 is an exploratory study with totals of control plus study arms of only 110 patients, it was not powered to a P inferior to 0.05 and the current trends looks promising |
| So we are now six to seven months away from seeing the final readout data of OVATION 2 program and this is an incredibly exciting time for Imunon |
| Our goal is to provide more potent and durable immunity for millions of people with cancer or infectious diseases, while creating significant value for our shareholders |
| The third quarter and recent weeks were exceptionally busy and full of achievements with more expected milestones to come |
| We continue to bolster our preclinical data set with PlaCCine, which suggests this asset has been de-risked and is performing as anticipated |
| And safety analyses continue to show good tolerability of IMNN-001 in this setting |
| I darn you guys are doing a good job, shepherding cash |
| In addition, our ability to rapidly switch out antigens and load multiple antigens into the same vaccine should be instrumental in addressing the spread of disease |
| And we are excited about reporting Phase II data here on next spring, next summer |
| Anwer presentation described the multiple advantages of PlaCCine over current commercial vaccine platforms, including multivariable antigen expression and T-cell responses versus protein and mRNA vaccines |
| So, we are excited about the body of preclinical data and we have been active in presenting this data at various conferences, both in the US and Europe |
| And, of course, as more centers come on board, you will see an acceleration in the enrollment |
| Have a very nice afternoon |
| As you know, patients receive PARP inhibitors, if they are BRCA-positive, even BRCA-negative patients get PARP inhibitors, as it has been demonstrated that it can increase progression free survival in HRD positive patients |
| Collaborations are a key component of our strategy and we are committed to ensuring that Imunon has the most talented advisors available to help us achieve our goal |
| We have generated compelling data in SARS-CoV-2 and IMNN-101, our next-generation COVID-19 seasonal booster, will be in the clinic in April with human clinical data expected in the second quarter of 2024 |
| So we believe that our PlaCCine modality is revealing itself as an important potential option in addressing not only pandemic response but also assist the seasonal vaccine option |
| Statement |
|---|
| For the nine months ended September 30, 2023, we reported a loss of $14.6 million or $1.64 per share |
| FixPlas concerns the application of our DNA technology to produce universal cancer vaccines, also called tumor-associated antigen cancer vaccines |
| Imunon reported a net loss for the third quarter of 2023 of $3.5 million or $0.37 cents per share |
| Operating expenses were six point -- I'm sorry $3.9 million in the current quarter, down 38% from the $6.3 million in the third quarter of 2022 |
| We did run into this issue back in 2012 with [Indiscernible], if you remember, that was a big issue |
| So I probably don't want to say anything over here because you did point out something and we haven't been really told that will be a concern with these centers, maybe a lot of small centers perhaps that could be an issue as there was with [Indiscernible] in about 25 sites or so |
| Operating expenses were $15.1 million in the first nine months of 2023, an 18% decrease from $18.4 million for the same period of 2022 |
| And that's a lot of variability there, IT there, there are several enzymes, some are deficient in some patients, some are not deficient in other patients |
| This compares with a net loss of $6.1 million, or $0.87 for the third quarter of 2022 |
| Jeff, outbacks been kind of turning down last few quarters |
| This compares with a net loss of $22.7 million or $3.42 for the same nine-month period of 2022 |
| Breaking down these items by line item; research and development expenses were $2 million, a decrease of $400,000 from the prior year's third quarter |
| Khursheed Anwer Vaccine trials efficacy is really now challenging human being right |
| And this is particularly important as many pathogens, such as Lassa virus may arise in geographies where there are challenges with refrigeration, storage and distribution networks |
Please consider a small donation if you think this website provides you with relevant information